Ingalls & Snyder LLC’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-1,295,833
| Closed | -$7.57M | – | 454 |
|
|
2022
Q4 | $7.57M | Sell |
1,295,833
-34,600
| -3% | -$182K | 0.41% | 51 |
|
|
2022
Q3 | $8.91M | Sell |
1,330,433
-80,720
| -6% | -$489K | 0.5% | 46 |
|
|
2022
Q2 | $5.94M | Buy |
1,411,153
+93,730
| +7% | +$371K | 0.31% | 62 |
|
|
2022
Q1 | $4.44M | Sell |
1,317,423
-41,150
| -3% | -$130K | 0.2% | 93 |
|
|
2021
Q4 | $4.28M | Sell |
1,358,573
-394,331
| -22% | -$1.31M | 0.19% | 95 |
|
|
2021
Q3 | $5.73M | Buy |
1,752,904
+24,004
| +1% | +$84.1K | 0.26% | 75 |
|
|
2021
Q2 | $7.3M | Buy |
1,728,900
+274,925
| +19% | +$1.16M | 0.32% | 66 |
|
|
2021
Q1 | $7.25M | Buy |
1,453,975
+91,772
| +7% | +$742K | 0.34% | 64 |
|
|
2020
Q4 | $17.2M | Sell |
1,362,203
-1,400
| -0.1% | -$16K | 0.85% | 30 |
|
|
2020
Q3 | $13.4M | Sell |
1,363,603
-18,445
| -1% | -$182K | 0.92% | 25 |
|
|
2020
Q2 | $13.8M | Sell |
1,382,048
-73,764
| -5% | -$707K | 0.79% | 33 |
|
|
2020
Q1 | $12.9M | Sell |
1,455,812
-9,900
| -0.7% | -$97.6K | 0.87% | 30 |
|
|
2019
Q4 | $13.5M | Sell |
1,465,712
-66,150
| -4% | -$469K | 0.73% | 37 |
|
|
2019
Q3 | $9.01M | Buy |
1,531,862
+172,487
| +13% | +$1.83M | 0.44% | 63 |
|
|
2019
Q2 | $16.3M | Buy |
1,359,375
+180,400
| +15% | +$1.94M | 0.78% | 32 |
|
|
2019
Q1 | $14.2M | Sell |
1,178,975
-2,000
| -0.2% | -$29.5K | 0.68% | 35 |
|
|
2018
Q4 | $14.8M | Sell |
1,180,975
-162,000
| -12% | -$2.24M | 0.78% | 31 |
|
|
2018
Q3 | $19.9M | Buy |
1,342,975
+5,113
| +0.4% | +$80.4K | 0.84% | 27 |
|
|
2018
Q2 | $22.5M | Buy |
1,337,862
+15,800
| +1% | +$307K | 1.05% | 19 |
|
|
2018
Q1 | $30.3M | Buy |
1,322,062
+7,500
| +0.6% | +$167K | 1.48% | 11 |
|
|
2017
Q4 | $34M | Buy |
1,314,562
+105,500
| +9% | +$2.12M | 1.57% | 11 |
|
|
2017
Q3 | $17.8M | Buy |
1,209,062
+153,062
| +14% | +$2.22M | 0.93% | 26 |
|
|
2017
Q2 | $14.7M | Hold |
1,056,000
| – | – | 0.8% | 35 |
|
|
2017
Q1 | $18M | Sell |
1,056,000
-12,300
| -1% | -$148K | 0.96% | 26 |
|
|
2016
Q4 | $11M | Buy |
1,068,300
+173,613
| +19% | +$1.59M | 0.6% | 42 |
|
|
2016
Q3 | $9.04M | Buy |
894,687
+270,187
| +43% | +$2.95M | 0.5% | 47 |
|
|
2016
Q2 | $7.01M | Buy |
624,500
+306,000
| +96% | +$3.9M | 0.41% | 53 |
|
|
2016
Q1 | $4.35M | Sell |
318,500
-51,141
| -14% | -$736K | 0.28% | 70 |
|
|
2015
Q4 | $7.01M | Sell |
369,641
-402
| -0.1% | -$8.74K | 0.45% | 48 |
|
|
2015
Q3 | $6.95M | Buy |
370,043
+1,543
| +0.4% | +$26.2K | 0.45% | 49 |
|
|
2015
Q2 | $5.49M | Hold |
368,500
| – | – | 0.3% | 68 |
|
|
2015
Q1 | $5.58M | Buy |
368,500
+17,500
| +5% | +$244K | 0.31% | 68 |
|
|
2014
Q4 | $4.67M | Buy |
+351,000
| New | +$4.53M | 0.27% | 71 |
|
Ingalls & Snyder LLC's CNCE Position: Q1 2023 in Review
Ingalls & Snyder LLC sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 1,295,833 shares — an estimated $7.57M sold.
Ingalls & Snyder LLC first reported a position in CNCE in Q4 2014 and held it in 33 quarters. The position peaked at $34M in Q4 2017. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Ingalls & Snyder LLC reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Ingalls & Snyder LLC sold 1,295,833 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $7.57M.
- Ingalls & Snyder LLC first reported a position in Concert Pharmaceuticals, Inc. in Q4 2014 and held it in 33 quarters.
- Ingalls & Snyder LLC's Concert Pharmaceuticals, Inc. position peaked at $34M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Ingalls & Snyder LLC's 13F filing for Q1 2023, filed 9 May 2023.